DNMT3A and acute myeloid leukemia: In summary, our data confirm that DNMT3A exon 23 mutations can be easily evaluated in medical practice and represent a frequent molecular event in intermediate-risk AML associated with NPM1 and FLT3-ITD mutations but have no clear impact on disease-free and overall survival.